Lamorola 25mg. 50mg. 100mg. 200mg Tablet.
PDF Leaflet Revision Date: 09 March 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Monotherapy or add-on treatment of partial epilepsy and Lennox-Gastaut syndrome.
Dosage (summary)
Adults: Start at 25 mg/day, increase to 100-200 mg/day. Children: 2 mg/kg/day, max 15 mg/kg/day.
Special Populations
- Hepatic impairment
- Renal impairment
- Elderly patients
Pregnancy & Breastfeeding
Safety in pregnancy and breastfeeding not established.
Key Drug Interactions
- Sodium valproate increases half-life
- Enzyme inducers decrease half-life
Contraindications
- Hypersensitivity to lamotrigine
- Hepatic or renal impairment
- Age over 65
Common side effects
- Rash
- Headache
- Dizziness
- Nausea
- Insomnia
Counselling Points
- Report any rash immediately
- Avoid abrupt discontinuation
- Monitor weight in children
Serious warnings
- Risk of serious skin reactions
- Abrupt withdrawal may cause rebound seizures
- Monitor for HLH symptoms
Important Disclaimer
The Lamorola 25mg. 50mg. 100mg. 200mg Tablet. professional information leaflet below is the property of Strides Pharma Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
